European doctors, represented by the European Association for the Study of Obesity (EASO), have officially recommended that Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs be used as the first-line treatment for obesity and its related complications. This recommendation was made public on Friday, October 3, 2025.

The recommendation emphasizes that these drugs, including Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, should be the primary medicines doctors consider when treating patients with obesity. The guidance reflects the growing clinical evidence supporting the efficacy of these medications in achieving significant weight loss and improving health outcomes.

EASO's endorsement comes amid rising obesity rates in Europe and the urgent need for effective medical interventions. The association noted that while these drugs should be the first choice for most patients, other treatments may be appropriate when only a smaller degree of weight loss is required.

The recommendation aims to guide healthcare providers across European countries in optimizing obesity management strategies, potentially improving patient quality of life and reducing obesity-related health complications.

Sources for this report include Reuters, Yahoo News, and MedWatch, which covered the announcement and provided detailed insights into the medical community's stance on these pharmaceutical treatments.